Contact Us

Yes. CDK2 rescue experiments are well-established for emerging CDK2 drug research: • Construct design: use a codon-modified CDK2 sequence with a small C-terminal tag (FLAG, HA). CDK2 has the canonical CDK architecture (PSTAIRE, T-loop with T160 activation site) — preserve all elements. • Kinase-dead rescue: K33R mutation in the ATP-binding lysine abolishes catalytic activity. • Functional readout: rescue should restore Cyclin E/A-CDK2 kinase activity, phospho-RB1 hyperphosphorylation, and S-phase progression. HEK293 transduces efficiently with lentivirus and supports stable rescue line generation for emerging CDK2-selective drug development.

The choice depends on whether you are studying CD9 (tetraspanin TSPAN29)'s role as a classical tetraspanin or modeling its functions in cell-cell fusion, exosome biology, and cancer metastasis. The Knockout line is the standard tool for asking whether CD9 is required for these processes — CD9 is a four-transmembrane tetraspanin that organizes tetraspanin-enriched microdomains (TEMs) at the cell surface, associating with integrins, ADAMs, and other partners; CD9 is essential for sperm-egg fusion (CD9 is on the oocyte), platelet aggregation, and is a classical exosome surface marker. Overexpression is useful for studying CD9 in heterologous expression contexts. For tetraspanin and exosome research, the EDITGENE CD9 Knockout in HEK293 enables systematic study of tetraspanin biology. Other tetraspanin family member (CD81, CD63, CD151) expression analysis aids interpretation. Rescue with wild-type CD9 is the standard specificity control. The knockout is valuable for studying CD9-mediated cell-cell interactions, CD9 as an exosome marker (CD9-null exosomes can be used to study CD9-dependent vs CD9-independent exosome cargo and function), and emerging CD9-targeted therapeutics in cancer metastasis research.

Yes. CD9 rescue experiments require attention to tetraspanin architecture: • Construct design: use a codon-modified CD9 sequence with a small intracellular tag (FLAG, HA). CD9 is a four-transmembrane tetraspanin with two extracellular loops (EC1, EC2) and intracellular termini — preserve membrane topology. • Surface localization validation: confirm plasma membrane localization by cell surface staining before functional assays. • Partner-binding-deficient rescue: EC2 loop mutations disrupt specific tetraspanin partner interactions. • Functional readout: rescue should restore CD9-dependent tetraspanin-enriched microdomain organization. HEK293 transduces efficiently with lentivirus and supports stable rescue line generation.

The choice depends on whether you are studying CLCN2 (chloride channel 2, CLC-2)'s role as a plasma membrane voltage-gated Cl⁻ channel or modeling leukoencephalopathy and CLCN2-mediated aldosteronism. The Knockout line is the standard tool for asking whether CLCN2 is required for these processes — CLCN2 is a CLC family member that, unlike CLC-7, functions as a true plasma membrane voltage-gated Cl⁻ channel activated by hyperpolarization, cell swelling, and acidic pH; CLCN2 has roles in maintaining cellular Cl⁻ homeostasis, brain extracellular ion balance, and aldosterone production. Overexpression is useful for studying CLCN2 gain-of-function effects. For neurological and endocrine research, the EDITGENE CLCN2 Knockout in HEK293 enables structure-function studies — CLCN2 biallelic loss-of-function mutations cause leukoencephalopathy with ataxia (LKPAT, brain white matter disease) and infertility; gain-of-function mutations cause familial hyperaldosteronism type II. Rescue with wild-type, channel-dead, or disease-mutant CLCN2 enables comprehensive disease modeling. The knockout is valuable for studying voltage-gated Cl⁻ channel biology, leukoencephalopathy mechanisms, and aldosterone production regulation.

Yes. CLCN2 rescue experiments require attention to plasma membrane voltage-gated channel architecture: • Construct design: use a codon-modified CLCN2 sequence with a small intracellular tag (FLAG, HA). CLCN2 has the canonical CLC architecture — preserve membrane topology. • Surface localization validation: confirm plasma membrane localization before electrophysiology assays. • Channel-dead rescue: gating residue mutations abolish hyperpolarization-activated Cl⁻ currents. • Familial hyperaldosteronism mutation rescue: gain-of-function mutations (G24D, R172Q, Y26N) enable disease modeling. • Functional readout: rescue should restore hyperpolarization-activated Cl⁻ currents by patch clamp. HEK293 transduces efficiently with lentivirus and supports stable rescue line generation for systematic CLCN2 mutation analysis.

The choice depends on whether you are studying CMTM6 (CKLF-like MARVEL transmembrane domain containing 6)'s role as a PD-L1 chaperone or modeling emerging PD-L1 regulatory mechanisms in cancer immunology. The Knockout line is the standard tool for asking whether CMTM6 is required for these processes — CMTM6 was identified through unbiased genome-wide haploid genetic screens (Burr et al. Nature 2017; Mezzadra et al. Nature 2017) as the critical regulator of PD-L1 surface expression and stability; CMTM6 colocalizes with PD-L1 at the plasma membrane and in recycling endosomes, protecting PD-L1 from lysosomal degradation by interfering with STUB1-mediated ubiquitination. Overexpression is useful for studying CMTM6 gain-of-function effects on PD-L1. For cancer immunotherapy research, the EDITGENE CMTM6 Knockout in HEK293 is highly informative — CMTM6 loss reduces PD-L1 surface levels by 50-90% in multiple cancer cell lines and enhances anti-tumor T cell activity, identifying CMTM6 as an emerging cancer immunotherapy target distinct from canonical anti-PD-L1 antibodies. CMTM4 paralog expression analysis aids interpretation given partial functional overlap. Rescue with wild-type CMTM6 enables structure-function studies. The knockout is valuable for studying PD-L1 trafficking and stability biology, and as a critical specificity tool for emerging CMTM6-targeted immunotherapy approaches (complementary to direct anti-PD-L1 therapy such as atezolizumab, durvalumab, avelumab).

Yes. CMTM6 rescue experiments are well-established for PD-L1 regulatory research: • Construct design: use a codon-modified CMTM6 sequence with a small intracellular C-terminal tag (FLAG, HA). CMTM6 has four-transmembrane MARVEL domain architecture — preserve membrane topology. • Surface/membrane localization validation: confirm appropriate subcellular localization before PD-L1 surface expression assays. • CMTM4 paralog studies: CMTM4 expression analysis given partial functional overlap. • Functional readout: rescue should restore PD-L1 surface expression measured by flow cytometry (PD-L1/CD274 staining) and protein stability (cycloheximide chase). HEK293 transduces efficiently with lentivirus and supports stable rescue line generation.

The choice depends on whether you are studying ATG7's role as the essential E1-like enzyme for autophagy or modeling autophagy deficiency in mammalian cells. The Knockout line is the standard tool for asking whether ATG7 is required for canonical autophagy — ATG7 is a ubiquitin-activating (E1)-like enzyme that activates two ubiquitin-like proteins: ATG12 (conjugated to ATG5) and LC3/GABARAP family members (lipidated to phosphatidylethanolamine, generating LC3-II); ATG7 activity is absolutely essential for canonical autophagy. Overexpression is useful for studying ATG7 gain-of-function effects. For autophagy research, the EDITGENE ATG7 Knockout in HEK293 is the gold-standard autophagy-deficient cell model — ATG7 KO abolishes LC3-II formation, ATG12-ATG5 conjugation, and canonical macroautophagy. This product complements the parallel ATG12 Knockout in HAP1 (also available) for systematic autophagy machinery dissection. Rescue with wild-type or catalytically-dead ATG7 (C572S in the catalytic cysteine) enables structure-function studies. The knockout is valuable for studying autophagy biology, autophagy-dependent vs autophagy-independent cell death, and emerging ATG7-targeted approaches in cancer (autophagy inhibitors like hydroxychloroquine are in clinical development as cancer chemotherapy sensitizers).

Yes. ATG7 rescue experiments are gold-standard for autophagy research: • Construct design: use a codon-modified ATG7 sequence with a small C-terminal tag (FLAG, HA). ATG7 has N-terminal ATG12-interaction region, central ATP-binding region, and C-terminal LC3-interaction region — preserve all elements. • Catalytically-dead rescue: C572S mutation in the catalytic cysteine abolishes E1-like activity — gold-standard specificity control. • Functional readout: rescue should restore LC3-II formation, ATG12-ATG5 conjugation, and autophagic flux measured by LC3 puncta and p62 turnover. HEK293 transduces efficiently with lentivirus and supports stable rescue line generation.

The choice depends on whether you are studying CCNE1 (cyclin E1)'s role as the canonical G1/S cyclin or modeling CCNE1 amplification-driven cancer biology and CDK2 inhibitor sensitivity. The Knockout line is the standard tool for asking whether Cyclin E1 is required for these processes — CCNE1/Cyclin E1 partners with CDK2 at the G1/S boundary to drive DNA replication initiation; Cyclin E1 levels peak at G1/S and decline through SCF^FBXW7-mediated degradation; CCNE1 is amplified in ~10-20% of high-grade serous ovarian cancer, ~5-10% of breast cancer, and other malignancies, conferring sensitivity to CDK2 inhibitors. Overexpression is useful for studying CCNE1 amplification effects. For cancer biology research, the EDITGENE CCNE1 Knockout in HEK293 is uniquely valuable — CCNE1 is closely paired with CDK2 (the parallel CDK2 Knockout in HEK293 is also available), and CCNE1 amplification creates a therapeutic vulnerability targetable by CDK2-selective inhibitors. Rescue with wild-type or FBXW7-degradation-resistant CCNE1 enables cancer modeling. The knockout is a critical specificity tool for ⭐ tagtociclib (PF-07104091), BLU-222, INX-315 — CDK2-selective inhibitors in clinical development for CCNE1-amplified ovarian, breast, and endometrial cancer.

Yes. CCNE1 rescue experiments are well-established for cancer cell cycle research: • Construct design: use a codon-modified CCNE1 sequence with a small C-terminal tag (FLAG, HA). CCNE1 has N-terminal regulatory region with FBXW7 phosphodegron, cyclin-box domains, and C-terminal regions — preserve all elements. • FBXW7-resistant rescue: T62A and S384A mutations in the phosphodegron prevent SCF^FBXW7-mediated degradation, generating stable cyclin E1 — useful for studying CCNE1 amplification effects. • CDK2-binding-deficient rescue: cyclin-box mutations disrupt CDK2 partnership. • Functional readout: rescue should restore Cyclin E1-CDK2 kinase activity and CDK2 inhibitor sensitivity in CCNE1-amplified contexts. HEK293 transduces efficiently with lentivirus and supports stable rescue line generation for systematic CCNE1-CDK2 axis research.

The choice depends on whether you are studying CDK3's role as a less-characterized G1 CDK or modeling its specific functions distinct from CDK2. The Knockout line is the standard tool for asking whether CDK3 is required for these processes — CDK3 is closely related to CDK2 (~75% sequence identity in kinase domain) and partners with cyclin C to phosphorylate RB and E2F at G0/G1 exit; CDK3 is the most evolutionarily ancient G1 CDK with restricted tissue expression. Overexpression is useful for studying CDK3 gain-of-function effects. Important consideration: CDK3 expression is relatively low in many cell lines including HEK293 — single CDK3 knockout may show modest phenotypes if CDK2 compensates. Rescue with wild-type or kinase-dead CDK3 is the standard specificity control. The knockout is valuable for studying less-characterized G1 CDK biology and emerging CDK3-specific drug development.

Yes. CDK3 rescue experiments require attention to less-characterized CDK biology: • Construct design: use a codon-modified CDK3 sequence with a small C-terminal tag (FLAG, HA). CDK3 has the canonical CDK architecture — preserve all elements. • Kinase-dead rescue: ATP-binding lysine mutation abolishes catalytic activity. • Cyclin C partnership: rescue interpretation considers Cyclin C (CCNC) expression for activation. • Functional readout: rescue should restore CDK3-dependent G0/G1 exit kinetics. HEK293 transduces efficiently with lentivirus and supports stable rescue line generation.

The choice depends on the experimental question. CCDC82 (coiled-coil domain containing 82) is an emerging less-characterized gene with limited published functional data. The Knockout line is appropriate for asking whether CCDC82 is required for predicted activities — CCDC82 is a coiled-coil domain-containing protein with no established specific function in the current literature; CCDC family members have diverse roles including ciliary function, mitosis, and signaling. Overexpression is useful for studying CCDC82 in heterologous expression contexts. For discovery research, the EDITGENE CCDC82 Knockout in HEK293 provides a clean genetic background for characterizing emerging CCDC82 biology. Rescue with wild-type CCDC82 is the standard specificity control. The knockout is valuable for CCDC family discovery research, interactome analysis, and emerging functional characterization of less-studied genes.

Yes. CCDC82 rescue experiments require attention to less-characterized protein architecture: • Construct design: use a codon-modified CCDC82 sequence with a small C-terminal tag (FLAG, HA). CCDC82 has coiled-coil domain — preserve protein integrity. • Discovery-oriented rescue: parallel wild-type rescue during phenotypic characterization distinguishes CCDC82-dependent phenotypes. • Functional readout: rescue should restore CCDC82-dependent phenotypes identified during knockout characterization. HEK293 transduces efficiently with lentivirus and supports stable rescue line generation.